Medcity新闻报道的关于生命科学近期时事的回顾
2012-05-28 11:54:54 来源：
丁香园 作者： 评论：0 点击：
Quintiles report: Healthcare payers to get greater drug development role. The Quintiles report says that lack of payer involvement in drug development indicates that pharmas are not interacting with their customers, who are increasingly the payers rather than physicians and patients. Payers will be pressing for greater communication.
昆泰公司报道：卫生保健投资者在药物开发过程中的的作用增加。昆泰公司报道，投资者对药物开发过程缺乏干预表明制药公司不能与其客户很好的交流，相对于医生和患者，这些客户中投资者的数量越来越多。
5 niche markets for telemedicine. Pennsylvania’s move this week to expand its telemedicine programto include more specialties reflects a broader trend of states using this tactic to improve healthcare access in underserved communities. Some specialized markets have emerged. For entrepreneurs and investors eyeing the telemedicine space, here are six niche spaces to watch.
5个远程医疗的小众市场。本周，吸引更多的专家参与以扩大远程医疗的范围的活动在宾夕法尼亚州举办，该活动表明了美国运用此策略以提高不规范社区的卫生保健服务的大的趋势。
5 innovative new solutions for treating diabetes. Solutions to the “whole body” problem of diabetes are coming from a wide variety of sources: the chairman of Whole Foods, innovative but largely unknown startups, entrenched industry giants and stem cell researchers, for example.
5项治疗糖尿病的革新办法。解决糖尿病“全身”问题的办法来自于各行各业：如Whole Foods公司的主席，创新但不为众人所知的新建公司，工业巨头以及干细胞研究人员。
Medtronic to partner with payers globally to leverage outcomes data. The strategy is being driven by a recognition that customers are not going to pay any amount of money for a therapy that works. They need products to be make sense from a cost perspective too. Or as Ishrak put it, “delivering economic value is increasingly becoming a critical factor in today’s changing healthcare environment.”
美敦力公司的全球合作对结果型数据发挥了杠杆作用。该策略正被顾客不会为有效的治疗付款的认知所影响。他们也需要从成本角度考虑有意义的产品。正如Ishrak所言：“在当今变化莫测的医疗环境中，经济利益的追求日益成为一项关键因素。”
Medtronic’s Symplicity system not enough to keep lead in renal denervation. Last week at the EuroPCR conference in Paris, “everyone and their mother,” as one analyst described it, showed off renal denervation products. Another analyst called it a “renal denervation deluge.” Competitors are St. Jude Medical, Covidien and Boston Scientific, along with smaller startups.
美敦力公司的Symplicity系统不足以在去肾交感神经研究者保持领先。上周在巴黎召开的巴黎血管重建论坛中，一位分析师在展示其公司的去肾交感神经产品时，将其公司形容为“去肾交感神经产品之母”。另一位分析师将其称作“去肾交感神经应用泛滥”。竞争对手包括St. Jude医疗公司，泰德公司，波士顿科学公司及其他的规模较小的新建公司。
昆泰公司报道：卫生保健投资者在药物开发过程中的的作用增加。昆泰公司报道，投资者对药物开发过程缺乏干预表明制药公司不能与其客户很好的交流，相对于医生和患者，这些客户中投资者的数量越来越多。
5 niche markets for telemedicine. Pennsylvania’s move this week to expand its telemedicine programto include more specialties reflects a broader trend of states using this tactic to improve healthcare access in underserved communities. Some specialized markets have emerged. For entrepreneurs and investors eyeing the telemedicine space, here are six niche spaces to watch.
5个远程医疗的小众市场。本周，吸引更多的专家参与以扩大远程医疗的范围的活动在宾夕法尼亚州举办，该活动表明了美国运用此策略以提高不规范社区的卫生保健服务的大的趋势。
5 innovative new solutions for treating diabetes. Solutions to the “whole body” problem of diabetes are coming from a wide variety of sources: the chairman of Whole Foods, innovative but largely unknown startups, entrenched industry giants and stem cell researchers, for example.
5项治疗糖尿病的革新办法。解决糖尿病“全身”问题的办法来自于各行各业：如Whole Foods公司的主席，创新但不为众人所知的新建公司，工业巨头以及干细胞研究人员。
Medtronic to partner with payers globally to leverage outcomes data. The strategy is being driven by a recognition that customers are not going to pay any amount of money for a therapy that works. They need products to be make sense from a cost perspective too. Or as Ishrak put it, “delivering economic value is increasingly becoming a critical factor in today’s changing healthcare environment.”
美敦力公司的全球合作对结果型数据发挥了杠杆作用。该策略正被顾客不会为有效的治疗付款的认知所影响。他们也需要从成本角度考虑有意义的产品。正如Ishrak所言：“在当今变化莫测的医疗环境中，经济利益的追求日益成为一项关键因素。”
Medtronic’s Symplicity system not enough to keep lead in renal denervation. Last week at the EuroPCR conference in Paris, “everyone and their mother,” as one analyst described it, showed off renal denervation products. Another analyst called it a “renal denervation deluge.” Competitors are St. Jude Medical, Covidien and Boston Scientific, along with smaller startups.
美敦力公司的Symplicity系统不足以在去肾交感神经研究者保持领先。上周在巴黎召开的巴黎血管重建论坛中，一位分析师在展示其公司的去肾交感神经产品时，将其公司形容为“去肾交感神经产品之母”。另一位分析师将其称作“去肾交感神经应用泛滥”。竞争对手包括St. Jude医疗公司，泰德公司，波士顿科学公司及其他的规模较小的新建公司。
上一篇：长期他汀类药物治疗对冠心病和肝功能异常患者心血管事件的预防效应及安全性评估
下一篇：患者如何通过脸谱网来寻求肾捐赠
论坛新帖
频道总排行
医学推广
频道本月排行
热门购物
评论排行
- 2011年临床执业医师考试实践技能真...(13)
- 腋臭手术视频(11)
- 2008年考研英语真题及参考答案(5)
- 节食挑食最伤女人的免疫系统(5)
- 核辐射的定义和单位(5)
- CKD患者Tm与IMT相关(5)
- 齐鲁医院普外科开展“喉返神经监护...(5)
- windows7激活工具WIN7 Activation v1.7(5)
- 正常微循环(5)
- 美大学性教育课来真的 男女上阵亲...(4)
